FREE SHIPPING ON ORDERS OVER $150

glp-1 receptor agonists effects on cardiovascular risk reduction and mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Glucagon-like peptide-1 receptor agonists' impact

$24.22

Quantity
- +
Description

doi:10.1515/jpem-2013-0122 90

glp-1 receptor agonists effects on cardiovascular risk reduction and mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Glucagon-like peptide-1 receptor agonists' impact

However, the differences between agents remain unexplored

glp-1 receptor agonists effects on cardiovascular risk reduction and mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Glucagon-like peptide-1 receptor agonists' impact

doi: 10.1161/CIRCULATIONAHA.117.028136

glp-1 receptor agonists effects on cardiovascular risk reduction and mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Glucagon-like peptide-1 receptor agonists' impact

Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF (2000) Osteoarthritis: new insights

glp-1 receptor agonists effects on cardiovascular risk reduction and mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Glucagon-like peptide-1 receptor agonists' impact

You may also like

recommand products